Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
CONCLUSION: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country.PMID:37116164 | DOI:10.31557/APJCP.2023.24.4.1401 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - April 28, 2023 Category: Cancer & Oncology Authors: Suttha Hamontri Tanitra Tantitamit Source Type: research
A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
J Gynecol Oncol. 2023 May;34(3):e52. doi: 10.3802/jgo.2023.34.e52. Epub 2023 Apr 10.ABSTRACTBACKGROUND: The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).METHODS: We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of com...
Source: Journal of Gynecologic Oncology - April 28, 2023 Category: OBGYN Authors: Ting Deng Kaijiang Liu Liang Chen Xiaojun Chen Hua Wen Li Hongyan Guo Huijiao Zhang Libing Xiang Xin Feng Xiaoyu Wang Hextan Ys Ngan Jianguo Zhao Dongling Zou Qing Liu Jihong Liu Source Type: research
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
CONCLUSION: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country.PMID:37116164 | DOI:10.31557/APJCP.2023.24.4.1401 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - April 28, 2023 Category: Cancer & Oncology Authors: Suttha Hamontri Tanitra Tantitamit Source Type: research
A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
J Gynecol Oncol. 2023 May;34(3):e52. doi: 10.3802/jgo.2023.34.e52. Epub 2023 Apr 10.ABSTRACTBACKGROUND: The Lymphadenectomy in Ovarian Neoplasms (LION) study revealed that systemic lymphadenectomy did not bring survival benefit for advanced ovarian cancer patients with clinically normal lymph nodes and was associated with a higher incidence of operative complications. However, there is no consensus on whether lymphadenectomy has survival benefit or not in early epithelial ovarian cancer (EOC).METHODS: We designed the LOVE study, a multicenter, randomized controlled, phase III trial to compare the efficacy and safety of com...
Source: Journal of Gynecologic Oncology - April 28, 2023 Category: OBGYN Authors: Ting Deng Kaijiang Liu Liang Chen Xiaojun Chen Hua Wen Li Hongyan Guo Huijiao Zhang Libing Xiang Xin Feng Xiaoyu Wang Hextan Ys Ngan Jianguo Zhao Dongling Zou Qing Liu Jihong Liu Source Type: research
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
CONCLUSION: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country.PMID:37116164 | DOI:10.31557/APJCP.2023.24.4.1401 (Source: Asian Pacific Journal of Cancer Prevention)
Source: Asian Pacific Journal of Cancer Prevention - April 28, 2023 Category: Cancer & Oncology Authors: Suttha Hamontri Tanitra Tantitamit Source Type: research
